224 related articles for article (PubMed ID: 31771255)
1. Determination of Stable Co-Amorphous Drug-Drug Ratios from the Eutectic Behavior of Crystalline Physical Mixtures.
Kissi EO; Khorami K; Rades T
Pharmaceutics; 2019 Nov; 11(12):. PubMed ID: 31771255
[TBL] [Abstract][Full Text] [Related]
2. Influence of the cooling rate and the blend ratio on the physical stability of co-amorphous naproxen/indomethacin.
Beyer A; Grohganz H; Löbmann K; Rades T; Leopold CS
Eur J Pharm Biopharm; 2016 Dec; 109():140-148. PubMed ID: 27746228
[TBL] [Abstract][Full Text] [Related]
3. Indomethacin co-amorphous drug-drug systems with improved solubility, supersaturation, dissolution rate and physical stability.
Fael H; Demirel AL
Int J Pharm; 2021 May; 600():120448. PubMed ID: 33675920
[TBL] [Abstract][Full Text] [Related]
4. Preparation and characterization of spray-dried co-amorphous drug-amino acid salts.
Jensen KT; Blaabjerg LI; Lenz E; Bohr A; Grohganz H; Kleinebudde P; Rades T; Löbmann K
J Pharm Pharmacol; 2016 May; 68(5):615-24. PubMed ID: 26245703
[TBL] [Abstract][Full Text] [Related]
5. Preparation and characterization of co-amorphous Ritonavir-Indomethacin systems by solvent evaporation technique: improved dissolution behavior and physical stability without evidence of intermolecular interactions.
Dengale SJ; Ranjan OP; Hussen SS; Krishna BS; Musmade PB; Gautham Shenoy G; Bhat K
Eur J Pharm Sci; 2014 Oct; 62():57-64. PubMed ID: 24878386
[TBL] [Abstract][Full Text] [Related]
6. Solid-Liquid Equilibrium in Co-Amorphous Systems: Experiment and Prediction.
Zemánková A; Hassouna F; Klajmon M; Fulem M
Molecules; 2023 Mar; 28(6):. PubMed ID: 36985463
[TBL] [Abstract][Full Text] [Related]
7. Tannic acid as a co-former in co-amorphous systems: Enhancing their physical stability, solubility and dissolution behavior.
Fael H; Demirel AL
Int J Pharm; 2020 May; 581():119284. PubMed ID: 32243965
[TBL] [Abstract][Full Text] [Related]
8. Amino acids as co-amorphous stabilizers for poorly water soluble drugs--Part 1: preparation, stability and dissolution enhancement.
Löbmann K; Grohganz H; Laitinen R; Strachan C; Rades T
Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):873-81. PubMed ID: 23537574
[TBL] [Abstract][Full Text] [Related]
9. Coamorphous drug systems: enhanced physical stability and dissolution rate of indomethacin and naproxen.
Löbmann K; Laitinen R; Grohganz H; Gordon KC; Strachan C; Rades T
Mol Pharm; 2011 Oct; 8(5):1919-28. PubMed ID: 21815614
[TBL] [Abstract][Full Text] [Related]
10. The formation and physical stability of two-phase solid dispersion systems of indomethacin in supercooled molten mixtures with different matrix formers.
Semjonov K; Kogermann K; Laidmäe I; Antikainen O; Strachan CJ; Ehlers H; Yliruusi J; Heinämäki J
Eur J Pharm Sci; 2017 Jan; 97():237-246. PubMed ID: 27890595
[TBL] [Abstract][Full Text] [Related]
11. Raman imaging of amorphous-amorphous phase separation in small molecule co-amorphous systems.
Kilpeläinen T; Pajula K; Ervasti T; Uurasjärvi E; Koistinen A; Korhonen O
Eur J Pharm Biopharm; 2020 Oct; 155():49-54. PubMed ID: 32795500
[TBL] [Abstract][Full Text] [Related]
12. Long-Term Stability of New Co-Amorphous Drug Binary Systems: Study of Glass Transitions as a Function of Composition and Shelf Time.
Martínez LM; Videa M; Sosa NG; Ramírez JH; Castro S
Molecules; 2016 Dec; 21(12):. PubMed ID: 27983640
[TBL] [Abstract][Full Text] [Related]
13. Spray drying of poorly soluble drugs from aqueous arginine solution.
Ojarinta R; Lerminiaux L; Laitinen R
Int J Pharm; 2017 Oct; 532(1):289-298. PubMed ID: 28890173
[TBL] [Abstract][Full Text] [Related]
14. Performance comparison between crystalline and co-amorphous salts of indomethacin-lysine.
Kasten G; Nouri K; Grohganz H; Rades T; Löbmann K
Int J Pharm; 2017 Nov; 533(1):138-144. PubMed ID: 28947246
[TBL] [Abstract][Full Text] [Related]
15. Properties of the Sodium Naproxen-Lactose-Tetrahydrate Co-Crystal upon Processing and Storage.
Sovago I; Wang W; Qiu D; Raijada D; Rantanen J; Grohganz H; Rades T; Bond AD; Löbmann K
Molecules; 2016 Apr; 21(4):509. PubMed ID: 27104502
[TBL] [Abstract][Full Text] [Related]
16. Indomethacin-omeprazole as therapeutic hybrids? Salt and co-amorphous systems enhancing physicochemical and pharmacological properties.
Nascimento ALCS; Martins ICB; Spósito L; Morais-Silva G; Duarte JL; Rades T; Chorilli M
Int J Pharm; 2024 Mar; 653():123857. PubMed ID: 38281693
[TBL] [Abstract][Full Text] [Related]
17. Co-amorphous systems consisting of indomethacin and the chiral co-former tryptophan: Solid-state properties and molecular mobilities.
Holzapfel K; Rades T; Leopold CS
Int J Pharm; 2023 Apr; 636():122840. PubMed ID: 36921746
[TBL] [Abstract][Full Text] [Related]
18. Physical characterization and stability of amorphous indomethacin and ranitidine hydrochloride binary systems prepared by mechanical activation.
Chieng N; Aaltonen J; Saville D; Rades T
Eur J Pharm Biopharm; 2009 Jan; 71(1):47-54. PubMed ID: 18644443
[TBL] [Abstract][Full Text] [Related]
19. Eutectic Mixture Formation and Relaxation Dynamics of Coamorphous Mixtures of Two Benzodiazepine Drugs.
Valenti S; Cazorla C; Romanini M; Tamarit JL; Macovez R
Pharmaceutics; 2023 Jan; 15(1):. PubMed ID: 36678825
[TBL] [Abstract][Full Text] [Related]
20. Preparation of Amorphous Composite Particles of Drugs with Ursodeoxycholic Acid as Preclinical Formulations.
Tanida S; Yoshimoto A; Yoshida M; Uchiyama H; Kadota K; Tozuka Y
Chem Pharm Bull (Tokyo); 2019; 67(9):921-928. PubMed ID: 31474730
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
